Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026)
Cresco Labs' (CRLBF) quarterly Income from Non-Controlling Interests came in at -$3.9 million in Q1 2026, down 391.52% YoY from $1.4 million in Q1 2025, and down 189.64% on a QoQ basis from -$1.4 million in Q4 2025.
Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$3.9 million in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 391.52% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (down 177.69% YoY) and the FY2025 annual result came in at -$4.6 million, down 133.24% from the prior year.
- Income from Non-Controlling Interests slipped to -$3.9 million in Q1 2026, from -$1.4 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $6.5 million in Q3 2022 to a low of -$19.3 million in Q4 2022.
- A 5-year average of -$162058.8 and a median of $2.2 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests slumped 783.66% — and 2024, when it surged 278.19%.
- Tracing CRLBF's Income from Non-Controlling Interests over 5 years: stood at -$19.3 million in 2022, then soared by 111.58% to $2.2 million in 2023, then surged by 115.45% to $4.8 million in 2024, then tumbled by 128.29% to -$1.4 million in 2025, then sank by 189.64% to -$3.9 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$3.9 million (Q1 2026), -$1.4 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Cresco Labs | 297.83 Mn | 233.72 Mn | 86.95 Mn | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.94 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -4.91 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | -802,000.00 |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | -6.93 Mn |
| Mar 31, 2023 | -1.76 Mn |
| Dec 31, 2022 | -19.29 Mn |
| Sep 30, 2022 | 6.54 Mn |
| Jun 30, 2022 | 5.25 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 7.48 Mn |